Correct Answer: A. It is a GLP-2 analogue
Teduglutide is a recombinant human glucagon-like peptide-2 (GLP-2) analogue with a single amino acid substitution (alanine-2 to glycine) that confers resistance to dipeptidyl peptidase-IV (DPP-IV) inactivation, thereby extending its half-life. GLP-2 is an endogenous 33-amino acid peptide secreted by intestinal L-cells that acts on GLP-2 receptors located on subepithelial myofibroblasts and enteric neurons, promoting intestinal blood flow, mucosal growth, and nutrient absorption. Teduglutide is specifically indicated for short bowel syndrome (SBS) in patients with significant intestinal failure, where it enhances remaining bowel function and reduces parenteral nutrition/fluid dependence. The drug increases splanchnic blood flow, enhances mucosal thickness, and improves intestinal barrier function. In Indian clinical practice, while SBS is less common than in Western countries, teduglutide represents an important pharmacological option for select patients with severe intestinal malabsorption. The GLP-2 mechanism distinguishes teduglutide from other GIT agents like GLP-1 agonists (exenatide, dulaglutide) used in diabetes, making this classification the fundamental and testable concept in NEET PG pharmacology.
Why the other options are wrong
B. It is administered orally — This is wrong because teduglutide is a peptide drug that is rapidly degraded by gastric and intestinal proteases; it must be administered via subcutaneous injection (0.05 mg/kg once daily). Oral administration would result in complete inactivation before absorption. The NBE trap here exploits the assumption that GIT drugs are oral—students may conflate teduglutide with oral GLP-1 agonists (semaglutide tablets), but teduglutide's peptide nature mandates parenteral delivery. C. Its half-life is 6–8 hours — This is wrong because teduglutide has a half-life of approximately 1.3 hours in plasma, but the DPP-IV resistance engineered into the molecule allows it to exert prolonged biological effects on intestinal tissue despite rapid systemic clearance. The 6–8 hour figure may be confused with other peptide hormones or GLP-1 agonists. The NBE trap conflates pharmacokinetic half-life (short) with pharmacodynamic duration (longer due to tissue retention and receptor signaling), a common pitfall in peptide pharmacology. D. It is recommended for patients with colorectal cancer — This is wrong because teduglutide is contraindicated in active malignancy, including colorectal cancer, due to the risk of promoting tumor growth via GLP-2 receptor signaling on cancer cells and increased intestinal blood flow. Teduglutide is used in benign short bowel syndrome, not cancer. The NBE trap exploits the superficial association between 'GIT drug' and 'colorectal pathology,' but the mechanism of GLP-2 (promoting growth and angiogenesis) makes it oncologically dangerous rather than therapeutic.
High-Yield Facts
- Teduglutide = GLP-2 analogue with DPP-IV resistance; acts on subepithelial myofibroblasts to enhance mucosal growth and intestinal blood flow.
- Subcutaneous injection is the only route; peptide structure precludes oral bioavailability.
- Indication: short bowel syndrome with intestinal failure; reduces parenteral nutrition dependence in eligible patients.
- Plasma half-life ~1.3 hours but prolonged tissue effects due to DPP-IV resistance and receptor-mediated signaling.
- Contraindicated in active malignancy (including colorectal cancer) due to risk of tumor promotion via GLP-2 receptor signaling.
Mnemonics
GLP-2 vs GLP-1 GLP-2 = Growth (intestinal mucosa), Long-acting (tissue effects), Peptide (SC only). GLP-1 = Glucose (diabetes), Lower (weight), Pancreas (insulin). Use when distinguishing teduglutide from diabetes agents. Teduglutide Indication Memory SBS = Short Bowel Syndrome is the ONLY approved indication for teduglutide in India and globally. Think: Short bowel → Subcutaneous teduglutide. Avoid colorectal cancer (contraindicated).
NBE Trap
NBE pairs 'GIT pharmacology' with 'colorectal disease' to lure students into selecting the cancer option, exploiting the superficial association between drug class and organ system while ignoring the contraindication logic. Additionally, the oral route trap exploits the assumption that GIT drugs are always oral, conflating teduglutide with small-molecule GIT agents.
Clinical Pearl
In Indian tertiary centres, teduglutide is rarely used due to cost and limited SBS prevalence, but recognizing it as a GLP-2 analogue is essential for NEET PG—the distinction from GLP-1 agonists (common in diabetes practice) is a high-yield discriminator. Clinically, the drug's angiogenic properties make it a growth-promoting agent, not a cancer treatment.
_Reference: KD Tripathi Pharmacology Ch. 59 (GIT Agents); Harrison Ch. 297 (Malabsorption); Robbins Ch. 17 (Intestinal adaptation)_